PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS

Documenti analoghi

• PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
  di: Brett Stevens, et al.
  Pubblicazione: (2023-08-01)
• Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival
  di: Margarita Dzama-Karels, et al.
  Pubblicazione: (2025-12-01)
• Research progress in Menin-MLL interaction and its inhibitors in MLL-rearranged leukemia
  di: FANG Xinyue, et al.
  Pubblicazione: (2024-10-01)
• Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
  di: Warren Fiskus, et al.
  Pubblicazione: (2023-04-01)
• Development of an orally bioavailable selective inhibitor of the menin-MLL
  di: Hai-Jing Zhong, et al.
  Pubblicazione: (2023-09-01)